Background
==========

Multiple myeloma (MM) is a malignant plasma cell disease, characterized by the clonal proliferation of plasma cells in bone marrow, accounting for 10--15% of all hematological malignancies. Some Chinese experts predicted that there are about 200 000 cases in China \[[@b1-medscimonit-23-2636]\]. Several studies revealed that clinical outcome of patients is heterogeneous, and the pathogenesis of MM is not understood clearly \[[@b2-medscimonit-23-2636],[@b3-medscimonit-23-2636]\]. Therefore, exploration of pathogenic development of MM may help to improve MM patient outcome.

The extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling transduction pathway can be activated in response to extracellular stimuli, and has been reported to play an important role in several pathophysiological processes such as cell proliferation and cell death. After stimulation, ERK1/2 protein of the MEK/ERK signaling pathway is phosphorylated, leading to activation of downstream targets \[[@b4-medscimonit-23-2636]--[@b6-medscimonit-23-2636]\]. Recent studies found that abnormal activation of the MEK/ERK signaling pathway is involved in pathogenesis of many kinds of solid tumors and hematological malignancies, including MM \[[@b7-medscimonit-23-2636]--[@b14-medscimonit-23-2636]\]. Furthermore, the MEK/ERK signaling pathway participates in abnormal biological behavior of MM cells, induced by some intracellular or extracellular stimuli \[[@b15-medscimonit-23-2636],[@b16-medscimonit-23-2636]\]. In MM, abnormality of the MEK/ERK signaling pathway is recurrent and is detected only on the genomic level, not on the protein level \[[@b13-medscimonit-23-2636]\]. Furthermore, the correlation between ERK signaling pathway abnormality and survival time in MM patients has not been reported.

In this study, we detected the expression of phosphorylated-ERK1/2 (p-ERK1/2) protein in 60 bone marrow biopsy specimens obtained from newly diagnosed patients with MM. We analyzed the correlations among expression levels of p-ERK1/2 protein, clinicopathological characteristics, and survival data of these patients, aiming to gain insight into the potential role of the ERK1/2 signaling pathway in pathogenesis of MM and its prognosis value in newly diagnosed patients with MM.

Material and Methods
====================

Patients and samples
--------------------

A total of 60 formalin-fixed, paraffin-embedded bone marrow biopsy specimens were obtained from newly diagnosed patients with MM at Fujian Medical University Union Hospital (Fuzhou, China) from January 2012 to February 2015. Before bone marrow biopsy, no prior chemotherapy was administered in any case. This study was approved by the Ethics Committee of Fujian Medical University Union Hospital. The samples were collected with patient consent.

Immunohistochemistry and evaluation of p-ERK1/2 protein expression
------------------------------------------------------------------

The thickness of the sections was 5 μm. Antigen retrieval was carried out in 10 mmol/l sodium citrate buffer (pH 6.0) at 120°C for 5 min in a pressure cooker. Endogenous peroxidase activity was blocked with 3% H~2~O~2~ at 37°C for 10 min. Sections were incubated with p-ERK1/2 rabbit monoclonal antibody (CST-4370, dilution 1: 400) (Cell Signaling Technologies, USA) at 37°C for 60 min. Immunoreactive proteins were visualized with the MaxVision™ HRP-Polymer Anti-Rabbit IHC Kit (Maixin Bio, China) following the manufacturer's protocol. Negative control sections were treated without p-ERK1/2 antibody under the same experimental conditions. Lastly, sections were counterstained with hematoxylin and observed by microscopy (BX41 microscope, Olympus Corporation, Tokyo, Japan) in a number of high-power microscopic fields (magnification, ×400).

Evaluation of p-ERK1/2 protein expression was performed by 2 pathologists blinded to the clinicopathological and survival information of the patients, according to the intensity of cellular staining and the percentage of positively immunoreactive cells. If disagreement emerged regarding the same slide, the pathologists discussed it until a consensus score was achieved. The p-ERK1/2 protein was immunohistochemically stained yellow-brown in the cytoplasm and/or nuclei of plasma cells. The staining intensity was scored as \[[@b17-medscimonit-23-2636]\]: no staining, score 0; weak staining, score 1; moderate staining, score 2; and strong staining, score 3. The proportion of stained plasma cell was scored as: ≤5% positive cells, score 0; 6--25% positive cells, score 1; 26--50% positive cells, score 2; 51--75% positive cells, score 3; and ≥75% positive cells, score 4. The expression level of p-ERK1/2 protein was considered negative if the total score (intensity score and positive cells score) was 0, low if it was 1 or 2, and high if it was 3 or more.

Statistical analysis
--------------------

Clinical event end-points were evaluated by use of the International Myeloma Working Group criteria. Overall survival (OS) was measured from the date of diagnosis to the date of death or last follow-up. Death from all causes was included. Progression-free survival (PFS) was measured from the date of treatment start to the date of disease progression, relapse, or death, whichever came first. Survival time was measured until 31 December 2015.

The χ^2^ test (categorical variables) and Student's t-test (continuous variables) were used to analyze the correlation between expression levels of p-ERK1/2 protein and demographic and clinicopathological characteristics of newly diagnosed patients with MM. Kaplan-Meier method was used to plot the survival curves. The log-rank test was used to analyze the differences in these survival curves. The Cox regression model was used for multivariate analysis, with adjustments for characteristics that might be significant prognostic factors according to the univariate analysis. P\<0.05 was used as the criterion for statistical significance. SPSS19.0 software was used for statistical analysis.

Results
=======

Demographic and clinicopathological characteristics of MM patients
------------------------------------------------------------------

The demographic and clinicopathological characteristics of 60 newly diagnosed patients with MM are summarized in [Table 1](#t1-medscimonit-23-2636){ref-type="table"}. Ages of these patients ranged from 35 to 81. After bone marrow biopsy, all patients were treated with at least 2 courses of chemotherapy regimens containing bortezomib and/or thalidomide, and/or autologous hematopoietic stem cell transplantation. The median follow-up of all patients was 16.1 (0.3--48) months. During the follow-up period, 21 deaths occurred.

Expression of p-ERK1/2 in bone marrow biopsy specimens and its correlation with demographic and clinicopathological characteristics of MM patients
--------------------------------------------------------------------------------------------------------------------------------------------------

The immunohistochemistry (IHC) results showed that expression of p-ERK1/2 protein was positive in 47 of 60 bone marrow specimens. According to evaluation criterion of p-ERK1/2 protein expression, 60 newly diagnosed patients with MM were classified into 3 groups: 19 patients with high p-ERK1/2 expression (group A), 28 patients with low p-ERK1/2 expression (group B), and 13 patients without p-ERK1/2 expression (group C) ([Figure 1](#f1-medscimonit-23-2636){ref-type="fig"}, [Table 1](#t1-medscimonit-23-2636){ref-type="table"}).

The demographic and clinicopathological characteristics according to expression levels of p-ERK1/2 protein are listed in [Table 1](#t1-medscimonit-23-2636){ref-type="table"}. There were significant differences in 3 characteristics -- ISS staging, serum albumin (Alb) level, and serum β~2~-MG level -- among patients in these 3 groups. However, there were no significant differences in other characteristics such as age, sex, ECOG scoring, immunoglobulin (Ig) isotype, hemoglobin (Hb) level, platelet (Plt) counts, serum creatinine (Scr) level, serum lactate dehydrogenase (LDH) level, serum calcium (Ca) level, and therapeutic regimens containing bortezomib, thalidomide, and/or autologous hematopoietic stem cell transplantation (auto-HSCT) among patients in these 3 groups ([Table 1](#t1-medscimonit-23-2636){ref-type="table"}).

Correlation between expression of p-ERK1/2 protein and survival time in newly diagnosed patients with MM
--------------------------------------------------------------------------------------------------------

To elucidate the relationship between expression levels of p-ERK1/2 protein and survival time in newly diagnosed patients with MM, univariate Kaplan-Meier and multivariate Cox regression analysis were performed.

Univariate analysis showed that in MM patients, expression level of p-ERK1/2 protein was negatively associated with OS and PFS. The OS and PFS of patients in group A were shorter than those in group B and group C. Furthermore, there were no significant differences in OS and PFS between patients in group B and those in group C ([Figure 2](#f2-medscimonit-23-2636){ref-type="fig"}, [Table 2](#t2-medscimonit-23-2636){ref-type="table"}). In addition, the shorter OS in newly diagnosed patients with MM was significantly associated with high ISS staging, Scr ≥177 μmol/l, serum β~2~-MG ≥5.5 μmol/l, and serum Ca ≥2.75 mmol/l, and the shorter PFS was significantly associated with high ISS staging, high ECOG scoring, Scr ≥177 μmol/l, serum β~2~-MG ≥5.5 μmol/l, and serum Ca ≥2.75 mmol/l ([Table 2](#t2-medscimonit-23-2636){ref-type="table"}).

Multivariate analysis showed that in MM patients, high expression level of p-ERK1/2 protein was significantly associated with OS and PFS. Additionally, serum Ca ≥2.75 mmol/l was significantly associated with PFS, and serum β~2~-MG ≥5.5 μmol/l was significantly associated with OS ([Table 3](#t3-medscimonit-23-2636){ref-type="table"}).

Discussion
==========

MM is an incurable malignant plasma cell disease. A growing number of studies show that pathogenesis and clinical outcome of MM patients are highly heterogeneous \[[@b1-medscimonit-23-2636],[@b18-medscimonit-23-2636]--[@b21-medscimonit-23-2636]\]. Recent studies using gene expression profiling show that the MEK/ERK signaling pathway is abnormally activated in over 50% of MM patients \[[@b13-medscimonit-23-2636]\]. MEK/ERK signaling pathway inhibitor can show cytotoxicity on MM cells from newly diagnosed patients and MM cell lines *in vitro* \[[@b22-medscimonit-23-2636],[@b23-medscimonit-23-2636]\]. Furthermore, MEK inhibitor used alone or in combination with conventional chemotherapy showed weak or moderate cytotoxicity to MM cells *in vivo*, leading to partial remission in some refractory/relapse patients with MM in a clinical trial. Some clinical trials are ongoing to evaluated the efficacy of new MEK inhibitor on patients with MM \[[@b23-medscimonit-23-2636]\]. The above evidence indicates that inhibition of the MEK/ERK signaling pathway may be a useful strategy for MM treatment. However, there has been no published research on the effect of activated molecules in the MEK/ERK signaling pathway, such as p-ERK1/2, on protein level, and the correlation between p-ERK1/2 protein expression and survival time in newly diagnosed patients with MM has been not reported.

The present study shows that the positive rate of p-ERK1/2 in bone marrow biopsy specimens of newly diagnosed patients with MM is high (78.3%), in agreement with a previous study showing that activation of the ERK signaling pathway is common in myeloma \[[@b13-medscimonit-23-2636]\]. We then classified 60 patients into 3 groups according to expression levels of p-ERK1/2 protein, showing that expression levels of p-ERK1/2 were positively associated with ISS staging, serum albumin level, and serum β~2~-MG level in these patients. However, there were not significant differences in the other clinicopathological characteristics mentioned above among patients in these 3 groups.

Before analysis of the correlation between expression levels of p-ERK1/2 protein and survival time in newly diagnosed patients with MM, in these 3 groups we analyzed the therapeutic regimens that have been considered to benefit MM patient survival time \[[@b24-medscimonit-23-2636],[@b25-medscimonit-23-2636]\]. We also found that there was no significant difference in therapeutic regimens containing bortezomib and thalidomide, and auto-hematopoietic stem cell transplantation among patients in these 3 groups.

Subsequently, in univariate analysis, we found that expression levels of p-ERK1/2 protein, high ISS staging, serum Cr ≥177 μmol/l, serum β~2~-MG ≥5.5 μmol/l, and serum Ca ≥2.75 mmol/l were poor prognostic factor for PFS and OS of newly diagnosed patients with MM. Otherwise, high ECOG scoring was a poor prognostic factor for PFS, but not for OS, of newly diagnosed patients with MM.

In multivariate analysis, we found that in newly diagnosed patients with MM, high expression level of p-ERK1/2 protein, but not low expression level of p-ERK1/2 protein, was an independent poor prognostic factor for OS and PFS of newly diagnosed patients with MM. In addition, in newly diagnosed patients with MM, serum Ca ≥2.75 mmol/l was also an independent poor prognostic factor for PFS, while serum β~2~-MG ≥5.5 μmol/l was also an independent poor prognostic factor for OS.

Although ISS staging, consisting of serum albumin level and serum β~2~-MG level, has been reported to be the most important prognostic system for MM \[[@b21-medscimonit-23-2636]\], we found that it had no useful prognostic value. We found differences in ISS staging, serum albumin level, and serum β~2~-MG level in newly diagnosed patients with MM with different expression levels of p-ERK1/2 protein, and these differences might have attenuated the prognostic function of ISS staging in our study.

Conclusions
===========

Our data suggest that high expression of p-ERK1/2 protein is an independent factor for poor survival in newly diagnosed patients with MM, and therapeutic regimens targeting ERK1/2 may be of benefit to MM patients.
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![Immunohistochemical staining of p-ERK1/2 in bone marrow biopsy specimens of MM patients (magnification, ×400). Different expression levels of p-ERK1/2 protein were found in these specimens: (**A**) high expression, (**B**) low expression, and (**C**) negative.](medscimonit-23-2636-g001){#f1-medscimonit-23-2636}

![Kaplan-Meier survival curves of patients with newly diagnosed MM classified according to expression levels of p-ERK1/2 protein. (**A**) Overall survival. i. P=0.000, compared A with B; ii. P=0.007, compared A with C; iii. P=0.541, compared B with C. (**B**) Progression-free survival. i. P=0.000, compared A with B; ii. P=0.007, compared A with C; iii. P=0.496, compared B with C.](medscimonit-23-2636-g002){#f2-medscimonit-23-2636}

###### 

Demographic and clinicopathological characteristics of primary MM patients.

  Demographic and clinicopathological characteristics   Total   p-ERK1/2 expression (group)   P-value                                
  ----------------------------------------------------- ------- ----------------------------- ------------ ------------ ------------ ------
  Age (years)                                                                                 63.21±2.84   55.96±2.16   56.77±3.38   0.11
  Sex                                                   Male    36                            14           13           9            0.13
  Female                                                24      5                             15           4                         
  Ig isotype                                            IgG     29                            10           15           4            0.51
  IgA                                                   20      7                             7            6                         
  Light chain                                           11      2                             6            3                         
  ISS staging                                           I       12                            1            6            5            0.04
  II                                                    25      6                             14           5                         
  III                                                   23      12                            8            3                         
  ECOG scoring                                          0--1    48                            13           24           11           0.42
  2--4                                                  12      6                             4            2                         
  Plt (×10^9^/L)                                        ≥100    50                            15           23           12           0.59
  \<100                                                 10      4                             5            1                         
  Hb (g/L)                                              ≥100    19                            4            10           5            0.48
  \<100                                                 41      15                            18           8                         
  Scr (μmol/L)                                          ≥177    7                             4            1            2            0.17
  \<117                                                 53      15                            27           11                        
  Serum Alb (g/L)                                       ≥35     16                            2            7            7            0.02
  \<35                                                  44      17                            21           6                         
  Serum β~2~-MG (μmol/L)                                ≥5.5    19                            11           5            3            0.01
  \<5.5                                                 41      8                             23           10                        
  Serum LDH (IU/L)                                      ≥245    12                            5            6            1            0.42
  \<245                                                 48      14                            22           12                        
  Serum Ca (mmol/L)                                     ≥2.75   7                             4            2            1            0.30
  \<2.75                                                53      15                            26           12                        
  Bortezomib                                            Yes     27                            10           11           6            0.66
  No                                                    33      9                             17           7                         
  Thalidomide                                           Yes     35                            13           14           8            0.44
  No                                                    25      6                             14           5                         
  Auto-HSCT                                             Yes     10                            1            5            4            0.16
  No                                                    50      18                            23           9                         

Ig -- immunoglobulin; ISS -- International Staging System; ECOG -- Eastern Cooperative Oncology Group; Plt -- platelet; Hb -- hemoglobin; Scr -- serum creatinine; Alb -- albumin; β~2~MG -- β~2~-microglobulin; LDH -- lactate dehydrogenase; Ca -- calcium; Auto-HSCT -- autologous hematopoietic stem cell transplantation.

###### 

Univariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in primary MM patients.

  Demographic and clinicopathological characteristics   Overall survival time (mean, month)   Log-rank test   P             Progression-free survival time (mean, month)   Log-rank test   P        
  ----------------------------------------------------- ------------------------------------- --------------- ------------- ---------------------------------------------- --------------- -------- -------------
  Age                                                   ≥60                                   15.712          1.733         0.188                                          14.786          0.072    0.788
  \<60                                                  19.165                                15.836                                                                                                
  Sex                                                   Male                                  16.260          1.134         0.287                                          14.082          1.401    0.237
  Female                                                19.637                                17.286                                                                                                
  Ig isotype                                            IgG                                   17.347          0.070         0.966                                          14.686          0.059    0.809
  IgA                                                   17.650                                14.915                                                                                                
  Light chain                                           18.235                                17.966                                                                                                
  ISS staging                                           I                                     22.182          6.094         0.048                                          21.653          5.085    0.024
  II                                                    19.166                                14.766                                                                                                
  III                                                   13.535                                12.732                                                                                                
  ECOG                                                  0--1                                  18.206          0.989         0.320                                          16.251          4.148    0.042
  2--4                                                  15.230                                11.816                                                                                                
  Plt (×10^9^/L)                                        ≥100                                  17.250          1.111         0.292                                          15.286          0.190    0.663
  \<100                                                 19.413                                15.753                                                                                                
  Hb (g/L)                                              ≥100                                  21.189          1.678         0.195                                          18.657          2.705    0.100
  \<100                                                 15.953                                13.838                                                                                                
  Scr (μmol/L)                                          ≥177                                  10.110          7.047         0.008                                          9.396           5.169    0.023
  \<177                                                 18.602                                16.152                                                                                                
  Serum Alb (g/L)                                       ≥35                                   17.855          **\<0.001**   0.989                                          17.469          0.963    0.327
  \<35                                                  17.522                                14.598                                                                                                
  Serum β~2~-MG (μmol/L)                                ≥5.5                                  11.416          13.173        **\<0.001**                                    10.623          7.908    0.005
  \<5.5                                                 20.482                                17.561                                                                                                
  Serum LDH (IU/L)                                      ≥245                                  16.997          0.022         0.883                                          14.266          0.140    0.709
  \<245                                                 17.764                                15.638                                                                                                
  Serum Ca (mmol/L)                                     ≥2.75                                 8.781           15.119        **\<0.001**                                    7.372           22.136   **\<0.001**
  \<2.75                                                18.777                                16.419                                                                                                
  Bortezomib                                            Yes                                   17.371          0.020         0.887                                          15.159          0.001    0.979
  No                                                    17.820                                15.543                                                                                                
  Thalidomide                                           Yes                                   16.798          1.271         0.260                                          14.934          0.383    0.536
  No                                                    18.749                                15.965                                                                                                
  Auto-HSCT                                             Yes                                   19.983          0.491         0.483                                          17.020          0.171    0.679
  No                                                    17.136                                15.032                                                                                                
  p-ERK1/2 expression                                   High (A)                              9.792           23.674        **\<0.001**                                    8.604           8.673    0.003
  Low (B)                                               22.010                                19.028                                                                                                
  Negative (C)                                          19.564                                17.352                                                                                                

Ig -- immunoglobulin; ISS -- International Staging System; ECOG -- Eastern Cooperative Oncology Group; Plt -- platelet; Hb -- hemoglobin; Scr -- serum creatinine; Alb -- albumin; β~2~-MG -- β~2~-microglobulin; LDH -- lactate dehydrogenase; Ca -- calcium; Auto -- HSCT-autologous hematopoietic stem cell transplantation.

###### 

Multivariate analysis of the correlation between clinicopathological characteristics and survival time in primary MM patients.

  Covariates            Overall survival   Progression-free survival                                                                           
  --------------------- ------------------ --------------------------- ------- -------------- ------- -------- ------- ------- --------------- -------
  ISS staging           −0.097             0.257                       0.907   0.548--1.502   0.705   0.044    0.237   1.045   0.656--1.664    0.853
  Scr (μmol/L)          0.019              0.640                       1.019   0.290--3.574   0.977   −0.100   0.587   0.905   0.287--2.857    0.865
  β~2~-MG (μmol/L)      0.928              0.470                       2.530   1.006--6.358   0.048   0.432    0.436   1.541   0.656--3.618    0.321
  Ca (mmol/L)           1.010              0.619                       2.745   0.816--9.231   0.103   1.715    0.605   5.559   1.697--18.212   0.005
  p-ERK1/2 expression   −0.575             0.234                       0.563   0.355--0.891   0.014   −0.546   0.226   0.579   0.372--0.901    0.015
  ECOG                  N.A.               N.A.                        N.A.    N.A.           N.A.    0.544    0.348   1.722   0.870--3.407    0.118

ISS -- International Staging System; ECOG -- Eastern Cooperative Oncology Group; Scr -- serum creatinine; Alb -- albumin; β~2~-MG -- β~2~-microglobulin; Ca -- calcium; HR -- hazard ratio; CI -- confidence interval; N.A. -- not available.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
